IXICO plc (AIM: IXI), a global leader in neuroscience imaging and biomarker analytics, announced on 19 November 2026 the latest release of its proprietary AI-powered IXI™ platform alongside two new technology collaborations with Neuropacs Corp and ZRO Imaging. The platform update focuses on improving clinical trial operational efficiency, scalability, and image quality control. The new partnerships extend IXI™'s capabilities in Parkinson's disease differentiation and PET imaging for Alzheimer's disease and other neurodegenerative disorders, advancing IXICO's stated TechBio strategy.

Key Points

  • IXICO plc (AIM: IXI), a London-based global neuroscience imaging and biomarker analytics company
  • IXICO has released the latest version of IXI™ and announced technology collaborations with Neuropacs Corp and ZRO Imaging
  • Neuropacs Corp's FDA De Novo authorised neuropacs™ AIDP algorithm will add Parkinson's disease differentiation; ZRO Imaging will expand PET imaging and quantitative analysis tools for Alzheimer's and other neurodegenerative disorders
  • Investors may watch for further technology licensing deals and progress on recurring revenue generation through the IXI™ platform marketplace

IXI™ Platform Upgrade Targets Clinical Trial Efficiency and Commercial Scalability

The latest IXI™ release incorporates a significant programme of underlying technology development, advancing platform infrastructure, design, and user experience to deliver greater clinical trial operational efficiency and image quality control. The announcement states that work has also been conducted to extend the scalability of IXI™ for external commercial use, wider adoption, and integration with third-party technologies. IXICO describes this as delivering on its roadmap to pursue new commercial opportunities through technology licensing, integration, and strategic partnerships, targeting recurring revenue streams that complement its existing iCRO contract research services.

Neuropacs Corp Brings FDA-Authorised Parkinson's Diagnostic Algorithm to IXI™

Through its collaboration with Neuropacs Corp, IXICO will integrate the neuropacs™ AIDP algorithm into IXI™. The neuropacs™ AIDP system received FDA De Novo classification as the first-ever Parkinsonian syndrome diagnostic aid, designed to help clinicians differentiate Parkinson's disease from multiple system atrophy parkinsonian variant and progressive supranuclear palsy using free-water diffusion MRI. The announcement notes the tool is intended as a supplemental aid and should be interpreted alongside clinical evaluation and other diagnostic testing, not as a standalone diagnostic device — a risk factor relevant to its deployment in clinical trial and healthcare settings.

ZRO Imaging Partnership Expands IXICO's PET Imaging Capabilities Across Neurodegenerative Diseases

The collaboration with ZRO Imaging, a specialist neuroimaging company focused on advanced PET imaging and quantitative image analysis, will extend IXI™'s capabilities across PET methodologies and biomarker development for Alzheimer's disease and other neurodegenerative disorders. The announcement states that ZRO Imaging brings advanced PET imaging methodologies and quantitative analysis tools to the platform. Together with the Neuropacs Corp collaboration, IXICO states these additions are designed to position IXI™ as a one-stop marketplace for advanced neurological imaging biomarkers, simplifying customer access through a single integrated platform.

Citeline Biotech Awards 2026 Win Cited as Independent Validation of IXI™ Innovation

The announcement references IXICO winning Technology Innovation of the Year at the Citeline Biotech Awards 2026, which the company describes as independent validation of the capabilities underpinning IXI™. IXICO has a 20-year track record as an end-to-end imaging contract research organisation, having supported hundreds of neurological clinical trials and analysed hundreds of thousands of scans. The IXI™ platform hosts over 30 analytics algorithms and is described in the announcement as the only technology platform specifically built for and exclusively focused on neuroimaging processing and neurological biomarker analysis.